Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

HspE7

Known as: HPV 16 E7/HSP65 Vaccine, Verpasep Caltespen, BCG65-E7 
A recombinant chimeric protein composed of the heat shock protein 65 (Hsp65) from Mycobacterium bovis, and the human papilloma viral (HPV) protein E7… Expand
National Institutes of Health

Related topics

Related topics

6 relations
Antigen SensitizationCytotoxic T-LymphocytesT-Cell Activationimmunopotentiation
Expand

Narrower (1)

SGN-00101

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia.
PURPOSE Infection with oncogenic human papillomaviruses has been linked to the development of cervical neoplasia and cancer. The… Expand
Review
2008
Review
2008
Medical treatment of cervical intraepithelial neoplasia II, III: an update review
Cervical intraepithelial neoplasia (CIN) II, III is a preinvasive stage of squamous cell carcinoma of the uterine cervix. The… Expand
2007
2007
Induction of CD4-Independent E7-Specific CD8+ Memory Response by Heat Shock Fusion Protein
ABSTRACT Infection with human papillomavirus type 16 (HPV16) is strongly associated with a number of disease states, of which… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
2007
2007
Verpasep caltespen vaccine shows efficacy against cervical dysplasia
  • 2007
    • Corpus ID: 195119436
 
2007
2007
Gateways to clinical trials.
  • M. Bayes
  • Methods and findings in experimental and clinical…
  • 2007
    • Corpus ID: 25431539
Agomelatine, AGRO-100, AIDSVAX gp120 B/E, alfimeprase, aliskiren fumarate, ALVAC vCP1452, alvocidib hydrochloride, ambrisentan… Expand
Highly Cited
2005
Highly Cited
2005
HspE7 Treatment of Pediatric Recurrent Respiratory Papillomatosis: Final Results of an Open-Label Trial
Objectives: We sought to evaluate the effectiveness of HspE7, a recombinant fusion protein of Hsp65 from Mycobacterium bovis BCG… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Review
2005
Review
2005
Technology evaluation: HspE7 (Stressgen).
Stressgen is developing HspE7, a recombinant fusion protein comprising the human papillomavirus (HPV) E7 antigen and the heat… Expand
Review
2002
Review
2002
Activity of HspE7, a Novel Immunotherapy, in Patients with Anogenital Warts
AbstractPURPOSE: Human papillomavirus causes anogenital squamous intraepithelial lesions, warts, and cancer. Treatment of… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
2001
2001
Technology evaluation: HspE7, StressGen Biotechnologies Corp.
  • S. Hunt
  • Current opinion in molecular therapeutics
  • 2001
    • Corpus ID: 40214286
StressGen is developing HspE7 (SGN-00101) as a potential therapy for human papillomavirus (HPV)-associated conditions. It is a… Expand
2000
2000
Immunotherapy of a human papillomavirus type 16 E7-expressing tumor by administration of fusion protein comprised of Mycobacterium bovis BCG Hsp65 and HPV16 E7
Abstract Human papillomavirus type 16 (HPV16) infection has been linked to the development of cervical and anal dysplasia and… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE